Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Halozyme Therapeutics, Inc. develops innovative drug delivery and auto-injector technologies, primarily utilizing its ENHANZE platform with proprietary enzyme rHuPH20. It licenses its technology to biopharmaceutical partners for subcutaneous formulations, enhancing drug absorption and patient convenience. The company also markets proprietary products like Hylenex and XYOSTED, supporting collaborations with major pharma firms to improve injectable therapies and expand treatment options globally.
This description was generated via AI from an annual report. Updated about 1 year ago.